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Summary A study was made of the prognostic value of pretreatment measurements of tumour radiosensitivity (surviving fraction at 2 Gy,
SF2) in 128 patients with stage I-Ill carcinomas of the uterine cervix undergoing radiotherapy. The median follow-up time was 47 months. In
a univariate analysis stratifying patients according to the median value, radiosensitivity was a significant prognostic factor for overall survival,
local control and metastasis-free survival. The 5-year survival rate for tumours with SF2 values below the median was 81% and was
significantly greaterthan the rate of 51% forthose with SF2 values above the median. In bivariate analyses, SF2 was shown to be independent
of disease stage, tumour grade, patient age, colony-forming efficiency and tumour diameter. In a multivariate analysis, radiosensitivity was the
most important variable and, after allowing for this, only stage was a significant independent predictor of treatment outcome. These data
indicate that, in carcinoma of the cervix treated with radiotherapy, pretreatment tumour intrinsic radiosensitivity is an important prognostic
parameter and contributes to prognosis independently of other established and putative parameters.
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There are considered to be three important radiobiological factors
that determine how well a tumour responds to radiotherapy:
intrinsic radiosensitivity, hypoxia and proliferation. The clinical
relevance of these parameters is currently receiving considerable
attention, and studies have been published suggesting the potential
ofall three as prognostic factors for radiotherapy (West, 1994).
In carcinoma of the cervix, our own studies have indicated that
tumour radiosensitivity is an important determinant of treatment
outcome (West et al, 1991, 1993). In this work, radiosensitivity is
measured using a soft agar clonogenic assay as surviving fraction
after 2 Gy in vitro irradiation (SF2). Some support for our finding
has come from work on head and neck tumours, which has shown
that radiosensitivity, measured using a growth assay as the initial
slope of radiation survival curves (a), significantly influenced
patient outcome when a high (above median) value was used to
stratify data (Girinsky et al, 1994). Other smaller studies using a
variety ofassays have also suggested thatradiosensitive tumours are
more responsive to therapy (Hinkley and Bosanquet, 1992; Ramsay
et al, 1992; Vaughan et al, 1993; Shibamoto etal, 1994). Studies that
have shown no relationship between tumour radiosensitivity and
treatment outcome either involved the establishment of cell lines
before assay (Allalunis-Turner et al, 1992; Schwartz et al, 1992;
Taghian et al, 1993) or treatment with surgery plus radiotherapy
(Brock et al, 1992), both ofwhich may be confounding influences.
This paper forms an update of a previous study (West et al,
1993) and now includes 128 patients compared with the original
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88 patients. In this report, for the first time, a multivariate analysis
has been performed to study the independence of SF2 as a prog-
nostic factor for carcinoma ofthe cervix treated with radiotherapy.
MATERIALS AND METHODS
Patient details
The patient details, treatment protocols and assay method have
been described in detail elsewhere (West et al, 1993). The study
was performed after South Manchester Medical Research Ethics
Committee approval, and only women with stage I-III proven
carcinoma ofthe cervix who gave informed consent were included
in the study. Tumour histological type was mainly squamous cell
carcinoma (n = 118) with eight adenocarcinoma and two adeno-
squamous cell carcinoma. The median patient age at the start of
treatment was 51 years with a range of 23-78 years. Tumour size
was measured either by magnetic resonance imaging (MRI)
(n = 39) to obtain an average diameter from three planes (ante-
rior-posterior, lateral and craniocaudal) or by clinical examination
(n = 37). The median tumour diameter was 4 cm with a range of
1-8 cm. For tumours for which both MRI and clinical size data
were available (n = 26), the MRI figures were used. There was
however no significant difference between the two measurements,
and only 1 of the 26 tumours had a tumour that was greater than
the median diameterby clinical examination but was smaller when
measured by MRI. Treatment was with radical (i.e. with curative
intent) radiotherapy alone, and follow-up times ranged from 2 to
5 years with a median of 47 months. Women suspected of pelvic
recurrence within the radiation field were reassessed and the recur-
rence was confirmed histologically and/or using radiological
techniques. The recurrences were divided into central (i.e. central
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pelvic recurrence), peripheral (i.e. those occurring at the edge of
the radiation field) and metastatic. Recurrence on the pelvic side-
wall was taken as being peripheral for external beam-irradiated
tumours or as being metastatic disease for those treated solely with
intracavitary irradiation.
Clonogenic assay
Tumour specimens were received immediately before the com-
mencement of radiotherapy. Samples were disaggregated using
an enzyme cocktail containing 0.4 mg mlr' DNAase, 0.5 mg ml
pronase and 0.5 mg ml' collagenase for 1.5 h followed by
0.05% trypsin for 0.5 h. Single-cell suspensions were cultured
using a soft agar clonogenic assay in Ham's F12 medium supple-
mented with 15% fetal calf serum, August rat red blood cells,
10 ng ml epidermal growth factor, 10 ,ug ml-' insulin, 0.5 ,ug ml'
hydrocortisone and 2.5,g ml' transferrin. Intrinsic radiosensi-
tivity was determined as sensitivity to a single in vitro dose of
2 Gy radiation (SF.2) after irradiation with a '37Cs y-source with a
dose rate of3.8-4.2 Gy min-'. SF. was calculated from the colony-
forming efficiencies of control and irradiated samples after
4 weeks growth in an atmosphere of 5% carbon dioxide plus 5%
oxygen plus 90% nitrogen. Larger samples were also irradiated
with 3.5 Gy to obtain SF33.
Immunohistochemical analysis of tumour colonies
The characterization of cells growing in colonies was carried out
using immunohistochemistry. Under a light microscope and using
a glass pipette, colonies were plucked from agar. The colonies
were exposed to trypsin and then the cells were placed onto slides
using a cytocentrifuge. Cells were fixed at room temperature in
acetone for 2 min. Cell staining was carried out with CAM5.3
(recognizing cytokeratins 8, 18 and 19; Becton-Dickenson) and
CKI (recognizing cytokeratins 6, 18; Dako) antibodies using the
alkaline phosphatase-anti-alkaline phosphatase (APAAP) method.
A mouse fibroblast strain (3T3) was used as a negative control.
Statistical analysis
The Mann-Whitney U-test was used to test for the level of signif-
icance of differences between data sets. The probabilities of
overall survival, locoregional control and metastasis-free survival
were determined using univariate and bivariate (stratified) log-
rank analysis, with the continuous variables grouped into two
(above and below median values) or three (for disease stage and
tumour grade) bands. As group boundaries corresponded to the
medians (SF2, age, volume), values falling on the boundaries
meant that, in practice, the data subsets were not always exactly
the same size. A stepwise multivariate Cox regression was also
performed to test for the independence of SF2 measurements from
clinical parameters. A significance level of 0.05 was used
throughout.
RESULTS
Validation of the assay used in this study has been reported else-
where (Davidson et al, 1990, 1992). Immunohistochemistry using
low-molecular-weight cytokeratins was used to suggest the
epithelial origin of colonies growing in agar. Nine tumours were
examined using CAM5.2 (recognizing cytokeratins 8, 18 and 19)
Table 1 Summary of SF2 values
Patient group n Median SF2 pa
All 128 0.42
Alive 85 0.38
Dead 43 0.53 <0.01
Recurrence 30 0.54 0.020
Central recurrence 15 0.57 0.020
Peripheral recurrence 18 0.47 0.21
Metastases and recurrence 38 0.52 0.010
Metastases only 21 0.49 0.070
aThe level of significance, using the Mann-Whitney test, of the median SF2
values for the various outcome groups vs the value for patients alive at the
time of analysis.
and CKl (recognizing cytokeratins 6, 18) antibodies and all
showed positive staining. Although the majority were positive
using both stains, two tumours were CAM5.2 positive and CKl
negative, showing the importance of using multiple cytokeratin
markers. Tumour colonies from two specimens were cultured in
repeat experiments for transmission electron microscopy,
and appearances were consistent with those of undifferentiated
epithelial cells.
Over the period of this study, 241 tumour samples were
received. Of these, 180 grew in culture representing an assay
success rate of 75%, 53 failed to meet the criteria for successful
growth (greater than ten colonies per control tube) and eight
cultures became infected. For some tumours, there was only
enough material for plating control tubes (n=13), and so the
success rate for obtaining SF, values was 71%. Assay errors and
success rates have also been described previously (West et al,
1989; Davidson et al, 1990; West et al, 1993). Only 128 ofthe 167
tumours were included in the study and the reasons for exclusion
were: stage IV disease, palliative treatment, treatment with
adjuvant chemotherapy. The mean, median and range of values
for colony-forming efficiency (CFE) were: 0.20%, 0.06% and
0.004-2.90% respectively.
Table 1 summarizes the SF2 values for the 128 patients included
in the study. The median value for SF, was 0.42 with a range of
0.14-0.93. Eighty-five patients were alive at the time of analysis
(including five intercurrent deaths at 11, 11, 18, 26 and 28
months), and these patients had a median SF2 of 0.38, which was
significantly lower than the value of 0.53 for 43 tumours from
patients dead of disease and 0.54 for 30 patients who developed
local recurrence. Five of the patients alive at the time of analysis
had recurrent disease, and this was either local (SF2 = 0.69, 0.79)
or metastatic (SF. = 0.32, 0.39, 0.49). Excluding these patients
from the 'alive' group did not affect the results of these analyses
(median SF2 value for 83 patients alive without recurrence = 0.38).
There is one finding that differs from our earlier analyses (West et
al, 1993). In the current analyses, the median tumour SF2 value
obtained for patients alive and well was not significantly different
from the median for those with peripheral recurrence (P = 0.21).
In the previous analysis, tumours that recurred peripherally were
significantly more radioresistant than the alive and well group.
Log-rank analysis of survival (Figure 1), stratifying according
to the median value, showed that SF2 was a significant prognostic
factor for survival (P = 0.0002), local control (P = 0.0013) and
metastasis-free survival (P = 0.0039). This analysis was repeated
with the SF2 values divided into four quartiles. Patient survival
decreased significantly with increasing tumour cell radioresistance
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Figure 1 Survival (A), local control (B) and metastasis-free survival (C) vs
SF2. The data from 128 patients have been stratified according to the median
SF2 value, and for all graphs the upper arm is for SF2<0.42. The numbers of
events per patients are given on each arm
with 8 out of32, 3 out of31, 14 out of30 and 17 out of35 deaths in
the four quartiles (P = 0.0019). This was accompanied with a
significant increase in the number ofpatients with local recurrence
(6 out of 32, 2 out of 31, 9 out of 30 and 13 out of 35 locoregional
failures; P = 0.005) and decrease in metastasis-free survival (7 out
of 32, 5 out of 31, 12 out of 30, 14 out of 35; P = 0.02). SF35 was
obtained for 67 patients. Using the median of this parameter to
stratify patients, those with radioresistant tumours suffered more
deaths and local recurrences than those with sensitive tumours, but
the differences were not significant in this smaller dataset (P = 0.06
for survival, P = 0.19 local control, P = 0.10 for metastasis-free
survival).
As expected, disease stage was a significant prognostic factor
(Figure 2). Patient survival decreased with advancing stage with 9
out of44, 18 out of49 and 16 out of35 deaths in stage I, II and III
disease respectively (P = 0.01). Although not significant, local
recurrence levels tended to increase with 7 out of44, 12 out of49
and 11 out of35 locoregional failures for stage I, II and III disease
respectively (P = 0.11). The number ofpatients developing metas-
tases also increased with stage (8 out of44, 18 out of49, 12 out of
35; P = 0.074). Neither patient age (n = 128, P = 0.85), tumour
grade (n = 117, P = 0.52) or tumour diameter (n = 76, P = 0.35)
were significantly associated with overall survival. Also, age
(P = 0.17, P = 0.41), grade (P = 0.24, P = 0.83) and diameter
(P = 0.21, P = 0.27) were not prognostic for either recurrence or
metastasis-free survival respectively.
In order to evaluate the independence of SF2 as a prognostic
factor, an evaluation was made of treatment outcome using
bivariate log-rank analyses. Patients were stratified according to
the median SF2 value after allowing for stage (Figure 3), grade,
age (Figure 4), colony-forming efficiency (CFE) and diameter
(Figure 5). In all cases, SF2 remained to be a significant prognostic
variable (Table 2). From these analyses, it was found that tumour
radiosensitivity was more important in stage III disease for
younger patients and in larger tumours. A multivariate Cox regres-
sion analysis was also carried out. This indicated that only SF2 and
stage were significant independent prognostic factors in this data
set (Table 3).
DISCUSSION
Two recent studies have reported the growth of fibroblasts in soft
agar clonogenic assays of tumours (Lawton et al, 1994; Stausbol
et al, 1995). In a study ofthree human lung tumours, the majority
(67-100%) of colonies examined after culture stained positively
with a fibroblast marker (Lawton et al, 1994). For the same
samples, only 34-75% ofcolonies stained positively with cytoker-
atin antibodies. The latter observation suggests cross-reactivity of
antibody staining, e.g. for one tumour eight out ofeight and three
out offour colonies were positive for a fibroblastand a cytokeratin
marker respectively. In our own work on cervix tumours, all the
colonies from nine tumours examined showed positive low-
molecular-weight cytokeratin staining, which is consistent with an
epithelial origin. However, it is recognized that cytokeratins have
been shown to cross-react with non-epithelial tissues, e.g. myo-
epithelial. It is also ofnote that we found that anegative result with
one source ofcytokeratin antibodies could be reversed by staining
with antibodies from another source, indicating the necessity of
using multiple low-molecular-weight cytokeratin markers to
identify cell types with a reasonable degree ofcertainty.
Indirect evidence for the tumour origin of colonies comes from
the demonstration that CFE was aprognostic factor for recurrence-
free survival in cervix patients. CFE is a very variable parameter,
and we have shown that measurements are associated with signifi-
cant intratumour and interexperiment variation (Davidson et al,
1992). Despite this variation, CFE was shown to be a significant
prognostic factor for local control in this analysis and in an earlier
analysis on fewer patients (West et al, 1993). In addition, within
the multivariate analysis, after allowing for tumour SF2 and stage,
CFE showed borderline significance for local control (Table 3).
CFE was not prognostic for overall survival. These findings are
consistent with CFE reflecting tumour stem cell content, which
would be more likely to predict for local control than for overall
survival in radiotherapy-treated disease (a CFE reflecting fibro-
blast growth (see above) would not be expected to relate to treat-
ment outcomes).
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Figure 2 Survival (A) and local control (B) vs disease stage. Patients were divided into stage 1, II and IlIl disease with 44, 49 and 35 patients, respectively, in
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Figure 3 Survival (A-C) and local control (D-F) vs SF2, stratified according to the median; for all graphs the upper arm is for SF2 <0.42. Patients were divided
into stage 1, 11 and IlIl disease with 44, 49 and 35 patients, respectively, in each group
This updated analysis confirms the findings from earlier
analyses performed on 51 (West et al, 1991) and 88 (West et al,
1993) patients. Considering the current interest in radiosensitivity
testing, there is a dearth of clinical studies measuring tumour
intrinsic radiosensitivity. However, as summarized in the
Introduction, there are several small studies that do confirm our
observation that radiosensitive tumours are more responsive to
radiotherapy (reviewed in West 1994, 1995). The importance of
tumour radiosensitivity was highlighted originally by Fertil and
Malaise (1981). In another paper (Malaise et al, 1987), these
authors published an analysis of the capacity of different survival
levels to identify significant differences between tumour radio-
responsiveness classes. The relationship was shown to be dose
dependent over the range 1-6 Gy with a bell-shaped curve and a
maximum at 1.5 Gy. The finding reported here for primary human
tumours thatSF3.5 was less effective than SF2 as a prognostic factor
for treatment outcomes supports the observations made on tumour
cell lines.
Obviously, it is important to examine the independence of any
putative prognostic factor. This has been highlighted in our own
work in a study of pretreatment measurements of serum markers
(CA125, SCC, TPA) in carcinomas of the cervix. Although all
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Table 2 The independence of tumour SF2 as a prognostic factor in carcinoma of the cervix treated with radiotherapy
n Survivala Local controla Metastasis-free survivala
Stage 128 0.0002 0.0014 0.0026
Grade 117 0.0005 0.0037 0.0051
Age 128 0.0002 0.0007 0.0021
CFE 128 0.0002 0.0016 0.0023
Diameter 76 0.0098 0.0006 0.028
aThe level of significance of SF2 as a prognostic factor after allowing for the listed parameters. Stratified log-rank analysis was used.
Table 3 Cox multivariate analysis showing the relative risk (RR) for survival and local recurrence-free survival
Variable Survival Local control
RR P RR P
SF2 (n = 128) 3.4 <0.001 6.4 <0.001
Stage
11 vs 2.11 0°007 NS 0.28
III vsl 3.6
CFE NS 0.93 NS 0.09
SF2 (n = 68) 4.0 0.001 16.2 <0.001
Stage
II vs 1.61 0.051 0.721 0.069
Ill Vs 4.1J 4.5
Upper values considered SF2, stage, CFE and age as candidates for the Cox model while the lower values
considered SF2, stage, CFE, age, grade and diameter, but with a smaller dataset. Only parameters that had a
significant prognostic value entered the Cox model. Non-significant terms (NS) had an RR not significantly
different from 1.
three markers were prognostic for treatment outcomes, after
allowing for disease stage in multivariate analyses, prognostic
significance was predominantly lost (Sproston et al, 1995). In the
current study with 128 women, the higher patient numbers have
now permitted multivariate analyses to be performed.
From the analyses, several observations can be made that add
strength to the finding that tumour radiosensitivity is an important
determinant of outcome after radiotherapy. The data show that
tumour radiosensitivity is more important in stage III disease and
for bulky tumours. The finding is consistent with a greater stem
cell content of larger tumours, resulting in a greater risk of loss of
tumour control perhaps because of insufficient radiation dose,
probably particularly so at the edge ofradiation fields (Figure SB).
For small-volume disease, tumour radiosensitivity would be less
important because of fewer tumour cells on the edge of radio-
therapy fields (Figure 5A). The same explanation can be used in
describing the importance of tumour radiosensitivity for different
stages of disease. The finding that tumour radiosensitivity is more
important for younger women is interesting and perhaps suggests
some hormonal influence for differences in pre- and post-
menopausal women.
In this study, neither tumour size, patient age nor histological
grade were significant prognostic factors. A number of studies
have shown that tumour size is an important prognostic variable in
carcinoma ofthe cervix treated with radiotherapy (e.g. Fyles et al,
1995). Possible reasons for the lack of significance of tumour size
in our study are the inclusion ofall three stages in the analysis (i.e.
different treatment methods), stratifying data according to the
median value and the low numbers of evaluable cases. Although
there are some reports of patient age and tumour grade as being
significant prognostic factors in cervix tumours (e.g. Prempree et
al, 1983), these have not been consistent findings (e.g. Russell et
al, 1989).
Our work shows that tumour radiosensitivity is important, but it
does not address the issue of whether tumour radiosensitivity
testing will be of clinical value. The clonogenic assay used in this
study is probably too laborious to be of routine clinical use. In
addition, it takes 4 weeks to generate results with only a 70%
success rate. There is clearly a need for a rapid and reliable test.
The future of tumour radiosensitivity testing will also be depen-
dent on the clinician's ability to offer alternative treatment. In
theory, dose escalation to radioresistant tumours could lead to
impressive increases in local control (West and Hendry, 1992), but
this strategy will be dependent on having a highly sensitive and
specific assay for normal tissue radiosensitivity. For some tumour
sites, e.g. head and neck cancers, extensive surgery might be an
alternative treatment to radiotherapy for some radioresistant
tumours. Radiosensitivity testing might also be used to examine
novel chemotherapeutic agents, and the potential of this is
illustrated in Figure 6 in which the importance of disease stage
is highlighted in patients with radioresistant tumours.
In conclusion, in this work we have confirmed our own earlier
observations that tumour radiosensitivity is an important determi-
nant of outcome after radiotherapy. In addition, the study has
shown that tumour radiosensitivity is independent of other estab-
lished and putative prognostic variables.
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